Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
47.00    -1.00 (-2.08%)
Bid:
46.50
Ask:
47.50
Spread: 1.00 (2.151%)
Market Cap: £90.17m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q4 2024 Update

23 Jan 2025 07:00

RNS Number : 3668U
Iofina PLC
23 January 2025
 

23 January 2025

 

Iofina plc

("Iofina", the "Company" or the "Group")

(AIM: IOF)

 

Q4 2024 Corporate Update

Record Full Year 2024 Iodine Production & IO#11 On Track

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides a brief update regarding its activities during Q4 2024 and an outlook for 2025.

 

In Q4 2024, Iofina Resources produced 194.1 metric tonnes (MT) of crystalline iodine from its seven IOsorb® plants in western Oklahoma, a Q4 record for Iofina. Iofina's seventh operating plant, IO#10, has achieved full iodine production from September 2024.

 

The total H2 2024 production of 358MT was within our forecast range. When combined with H1 2024 crystalline iodine production of 276.1MT, total production for the year was a record for the Company, up 13.4% to 634.1MT compared to 2023 production of 559.3MT.

 

The Company has benefitted from a strong spot raw iodine price in excess of H1 2024 levels and is currently above $70/kg. Prices are anticipated to remain at these higher levels throughout H1 2025 due to the continued robust global demand for iodine. IPBC product sales have performed particularly well for Iofina Chemical in 2024, significantly surpassing 2023 levels, driven by strong interest from customers.

 

In December 2024, confirmed sales of more than $2.0m, which had been dispatched to customers from the Iofina Chemical facility, were unexpectedly delayed due to cargo shipping and logistical issues beyond the Company's control. In line with the Group's accounting policies, these orders will now be credited as sales in January 2025. Consequently, the Group expects to report adjusted EBITDA for 2024 in the region of $7.5m, below the forecast range of $8.5m-$9m. The Company projects that without these unexpected delays, the Group would have met its forecasted adjusted EBITDA target range. The recognition of delayed sales in January 2025 has given the Group a stronger start to the year than previously forecast.

 

With IO#9 and IO#10 operating as expected, along with the legacy plants, we are forecasting total iodine production for H1 2025 in the range of 320MT-355MT (H1 2024: 276.1MT). The Group notes that, as usual, production will be weighted to the second half when warmer brine water temperatures and larger brine volumes improve efficiencies and total iodine output.

 

The Company's growth strategy remains firmly on track. Construction has begun for IO#11 in Iofina's newest core area, with the initial land work underway and major components in the process of being supplied. The plant is expected to be completed and operational in Q3 2025. Preliminary discussions regarding IO#12 are progressing positively, further demonstrating the Company's commitment to expanding and accelerating its production capabilities.

 

Finally, the Group continues its proud record of ensuring a safety-first approach throughout its operations and reports that it has had no lost time incidents since April 2021.

 

President and CEO, Dr. Tom Becker, commented:

"The Company, as expected, achieved record iodine production in 2024. Our business operations have gone from strength to strength throughout 2024 with the successful completion of our new plant IO#10, which is operating as expected, as well as strategic investment at Iofina Chemical. With the foundations for IO#11 currently being laid, we are on track to complete construction in Q3 2025. At the same time, we are making good progress in finalising plans for IO#12. These developments highlight our ongoing focus on rapidly executing our growth strategy in a prudent fashion.

 

"Whilst the December shipping delays to customers were certainly frustrating in terms of hitting our year-end earnings target, we are pleased with the Group's overall performance in FY24. These delayed sales have been recognised in January 2025, which underpins our forecast for 2025. With iodine prices currently above $70/kg, and expected higher iodine production compared to 2024, the current outlook for the year is very promising."

 

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

 

Enquiries:

 

Iofina plc

Dr. Tom Becker

CEO & President

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Canaccord Genuity Limited

Henry Fitzgerald-O'Connor/Harry Rees

Tel: +44 (0)20 7523 8000

 

Financial PR and Media Contact:

Yellow Jersey PR Limited

Charles Goodwin/Shivantha Thambirajah/Zara McKinlay

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

 

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina operates seven IOsorb® plants in Oklahoma and consistently uses technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high-quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products. Iofina Chemical celebrated its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFIFLEIFFIE
Date   Source Headline
20th May 20197:00 amRNSProposed Placing and Open Offer
14th May 20197:00 amRNSStatement regarding share price rise
1st May 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSQ1 2019 Market Update
1st Apr 20197:00 amRNSCompletion of Debt Restructuring
22nd Feb 20194:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSDebt Restructuring
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
22nd Jan 20197:00 amRNSChange of Registered Office
17th Jan 20197:00 amRNSMarket Update
20th Nov 20184:40 pmRNSSecond Price Monitoring Extn
20th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20187:00 amRNSDirector Appointment
18th Oct 20184:40 pmRNSSecond Price Monitoring Extn
18th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20187:00 amRNSQ3 2018 Update
20th Sep 20187:00 amRNSInterim Results
16th Jul 20187:00 amRNSH1 2018 Update
18th Jun 20187:00 amRNSMarket update
14th Jun 20187:00 amRNSGrant of Options
13th Jun 201811:30 amRNSResult of AGM
30th Apr 20187:00 amRNSFinal Results and Notice of AGM
18th Apr 20187:00 amRNSQ1 2018 Market Update
16th Apr 20181:30 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
20th Mar 20183:05 pmRNSHolding(s) in Company
15th Mar 20181:24 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSProduction commences at IO#7
30th Jan 20183:00 pmRNSHolding(s) in Company
15th Jan 20187:00 amRNSMarket Update
14th Dec 20177:00 amRNSMarket Update
16th Nov 20177:00 amRNSIO#7 Progress and Market Update
20th Oct 20174:40 pmRNSSecond Price Monitoring Extn
20th Oct 20174:35 pmRNSPrice Monitoring Extension
10th Oct 20177:00 amRNSQ3 2017 Market Update
22nd Sep 20177:00 amRNSInterim Results
12th Sep 20177:00 amRNSConstruction of IO#7 to Expand Iodine Production
14th Jul 20177:00 amRNSCorporate and Production Update
14th Jun 201712:15 pmRNSResult of AGM
13th Jun 201712:07 pmRNSSecond Price Monitoring Extn
13th Jun 201712:02 pmRNSPrice Monitoring Extension
8th Jun 201712:07 pmRNSSecond Price Monitoring Extn
8th Jun 201712:02 pmRNSPrice Monitoring Extension
7th Jun 201712:07 pmRNSSecond Price Monitoring Extn
7th Jun 201712:02 pmRNSPrice Monitoring Extension
6th Jun 201712:07 pmRNSSecond Price Monitoring Extn
6th Jun 201712:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.